Navigation Links
Signum Biosciences, Inc. Announces Collaborative Agreement with GlaxoSmithKline
Date:11/10/2011

PRINCETON, N.J., Nov. 10, 2011 /PRNewswire/ -- Signum Biosciences, Inc., a privately held biotechnology company, has entered into an agreement with GlaxoSmithKline (China) R&D Company Limited (GSK) to collaborate on Signum's phosphatase screening technology and Phosphoprotein Phosphatase 2A (PP2A).

The agreement provides Signum with research support and milestone payments.  GSK receives the exclusive right of Signum's proprietary phosphatase screening technology for GSK's research and development activities in neurosciences.

GSK and Signum will undertake a broad R&D collaboration to screen and identify PP2A targeted compounds including those bridging the link between PP2A methylation and tau hyperphosphorylation.  Signum's partnership with GSK furthers Signum's position as an innovative biotech company, advancing pioneering drug discovery and leveraging GSK's capabilities in research and development.

Maxwell Stock, President of Signum Biosciences, commented, "GSK is an ideal partner for Signum.  We will develop therapeutics using our phosphatase screening technology in an alliance that utilizes the expertise of both companies.  We are proud to be working in collaboration with a leading pharmaceutical company in innovative research and development.  Collaborations such as these allow partners to share knowledge, expertise and resources and thereby provide a highly effective way of progressing cutting edge research and developing an effective drug."  

About Signum Biosciences, Inc.

Signum, a Princeton, New Jersey- based biotechnology company, dedicated to developing small-molecule therapeutics derived from its Phosphatase platform to modulate signal transduction imbalances.  Through research on protein networks that control biological systems, Signum is developing therapeutic agents for Alzheimer's, Parkinson's and other neurodegenerative diseases.  Signum's technology provides many opportunities for the development of novel consumer products and pharmaceutical candidates.  For further information please visit www.signumbiosciences.com.


'/>"/>
SOURCE Signum Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Signum Biosciences Awarded Two Additional NIH Grants for Development of Topical Therapeutics
2. Signum Biosciences, Inc. Announces Commercial Launch of Arazine™
3. Signum Biosciences Awarded Phase II SBIR Grant by the NIH for the Treatment of Rosacea
4. Regado Biosciences, Inc. to Present at the Sofinnova Japan Biopharma Partnering Conference in Tokyo, Japan
5. Luminex Corporation Completes Acquisition of EraGen Biosciences, Inc.
6. Luminex Corporation Announces Agreement to Acquire EraGen Biosciences, Inc.
7. Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System
8. Regado Biosciences, Inc. Announces Presentation of the Results of the RADAR Phase 2b Clinical Trial of Its Anticoagulant System REG1 at the i2 Summit During the American College of Cardiology 2011 60th Annual Scientific Session & Expo in New Orleans
9. Regado Biosciences, Inc. Introduces REG3, a Novel Aptamer-Based Inhibitor of Glycoprotein VI and its Matched Active Control Agent, at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
10. Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
11. Regado Biosciences, Inc. Presents Two Abstracts on the Subcutaneous Depot Formulation of Pegnivacogin, a Nuclease-Stabilized RNA Aptamer, Direct Factor IXa Inhibitor and Part of the REG2 Anticoagulant System, at the American Heart Association (AHA)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... Md. , Sept. 22, 2017  As the ... Republican Senators Bill Cassidy (R-LA) and ... Information notes that the medical device industry is in ... medical device tax, the 2.3% excise tax on medical ... But they also want covered patients, increased visits and ...
(Date:9/19/2017)...   ZirMed Inc ., a recognized leader in cloud-based ... has been ranked #1 by its users for the seventh ... User Survey. ZirMed was recognized as the top-ranked end-to-end revenue ... centers over 200 beds and holds one of the longest ... history. ...
(Date:9/13/2017)...   OrthoAtlanta has been named the official orthopedic ... (AFHC) for the 2018 College Football Playoff (CFP) National Championship ... Stadium in Atlanta, Georgia . OrthoAtlanta is ... campaign, participating in many activities leading up to, and including ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... ... viewers the lowdown on sciatica in a new episode of "Success Files," which ... current events and innovation and investigates each subject in-depth with passion and integrity. ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... “America On ... Christian identity. “America On The Brink” is the creation of published author, William ... several great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the ... today its plans to open a flagship location in Covington, LA at 401 N. ... To Go store next to Office Depot in the Holiday Square shopping center. Its ...
(Date:10/12/2017)... ... 2017 , ... The American College of Medical Informatics (ACMI) will present the ... Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium ... a pioneer in the field of medical informatics, this prestigious award is presented to ...
(Date:10/12/2017)... ... October 12, 2017 , ... Dr. ... recently contributed a medical article to the newly revamped Cosmetic Town journal ... spotlights the hair transplant procedure known as Follicular Unit Extraction (FUE). ...
Breaking Medicine News(10 mins):